LLY·Healthcare·Pharma
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines?
Healthcare
LLY·Healthcare·Pharma
ABBV·Healthcare·Dividend Aristocrats
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises?
BNTX·Healthcare·Biotech
BioNTech Oncology Faces $1B Buyback Warning Before ASCO
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience?
REGN·Healthcare·Biotech
Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative?
HIMS·Healthcare
Hims & Hers Earnings: -14% Shock as GLP-1 Pivot Hits Margins
Are Hims & Hers Earnings just a temporary GLP-1 growing pain or the start of a tougher chapter for this…
LLY·Healthcare·Pharma
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit…
MRNA·Healthcare·Biotech
Moderna Hantavirus +12% Rally: Can The Surge Last?
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story?
CVS·Healthcare
CVS Health Earnings Rally as EPS Jumps to $2.57 and Outlook Rises
Can the latest CVS Health Earnings beat and upgraded outlook finally turn this battered healthcare giant into a convincing comeback…
MRK.DE·Healthcare
Merck Keytruda Rivalry Surges as Ivonescimab Stumbles
Is the latest ivonescimab setback a temporary stumble or a turning point in the Merck Keytruda Rivalry for lung cancer…
AMGN·Healthcare·Biotech
Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…